Parse Biosciences

Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.

By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enables samples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.

The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig.

Parse Biosciences headquartered in United States, North America, operates in the Biotechnology, Life Science, Genetics, Bioinformatics sector. The company focuses on Biotechnology and has secured $9.6B in funding across 96 round(s). With a team of 51-100 employees, Parse Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Parse Biosciences, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.